H.C. Wainwright tells investors in a research note that Compass Pathways (CMPS) is one of the most compelling stories in neuropsychiatry, and that COMP360’s differentiated profile positions it as a “transformative” treatment in treatment-resistant depression. The firm believes the current valuation fails to reflect the full scope of its opportunity across multiple large-market psychiatric disorders with COMP360 on track to become a blockbuster treatment, if approved. The firm reiterates a Buy rating and $45 price target on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPS:
- COMPASS Pathways: Positioned for Transformative Growth in Neuropsychiatry with COMP360 Advancements
- Optimistic Buy Rating for COMPASS Pathways: Strategic Trials and Strong Financial Position Bolster Confidence in COMP360’s Potential
- Buy Rating for COMPASS Pathways: Promising Phase 3 Trial Progress and Strong Financial Position
- Compass Pathways price target lowered to $15 from $23 at Canaccord
- Compass Pathways Reports 2024 Financial Results and Progress